Literature DB >> 11018071

Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.

L Zhang1, C Chung, B S Hu, T He, Y Guo, A J Kim, E Skulsky, X Jin, A Hurley, B Ramratnam, M Markowitz, D D Ho.   

Abstract

Despite prolonged treatment with highly active antiretroviral therapy (HAART), infectious HIV-1 continues to replicate and to reside latently in resting memory CD4(+) T lymphocytes, creating a major obstacle to HIV-1 eradication. It is therefore not surprising to observe a prompt viral rebound after discontinuation of HAART. The nature of the rebounding virus, however, remains undefined. We now report on the genetic characterization of rebounding viruses in eight patients in whom plasma viremia was undetectable throughout about 3 years of HAART. Taking advantage of the extensive length polymorphism in HIV-1 env, we found that in five patients who did not show HIV-1 replication during treatment, the rebound virus was identical to those isolated from the latent reservoir. In three other patients, two of whom had been free of plasma viremia but had showed some residual viral replication, the rebound virus was genetically different from the latent reservoir virus, corresponding instead to minor viral variants detected during the course of treatment in lymphoid tissues. We conclude that in cases with apparent complete HIV-1 suppression by HAART, viral rebound after cessation of therapy could have originated from the activation of virus from the latent reservoir. In patients with incomplete suppression by chemotherapy, however, the viral rebound is likely triggered by ongoing, low-level replication of HIV-1, perhaps occurring in lymphoid tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11018071      PMCID: PMC517816          DOI: 10.1172/JCI10565

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

Authors:  F García; M Plana; C Vidal; A Cruceta; W A O'Brien; G Pantaleo; T Pumarola; T Gallart; J M Miró; J M Gatell
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

2.  HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.

Authors:  A U Neumann; R Tubiana; V Calvez; C Robert; T S Li; H Agut; B Autran; C Katlama
Journal:  AIDS       Date:  1999-04-16       Impact factor: 4.177

3.  Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.

Authors:  P R Harrigan; M Whaley; J S Montaner
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

4.  Latent reservoirs of HIV: obstacles to the eradication of virus.

Authors:  T W Chun; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

5.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

6.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

7.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

Authors:  G M Ortiz; D F Nixon; A Trkola; J Binley; X Jin; S Bonhoeffer; P J Kuebler; S M Donahoe; M A Demoitie; W M Kakimoto; T Ketas; B Clas; J J Heymann; L Zhang; Y Cao; A Hurley; J P Moore; D D Ho; M Markowitz
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

8.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

9.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

Authors:  R M Gulick; J W Mellors; D Havlir; J J Eron; C Gonzalez; D McMahon; D D Richman; F T Valentine; L Jonas; A Meibohm; E A Emini; J A Chodakewitz
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

10.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

View more
  71 in total

1.  Latency and viral persistence in HIV-1 infection.

Authors:  J D Siliciano; R F Siliciano
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

2.  Identification of T cell-signaling pathways that stimulate latent HIV in primary cells.

Authors:  David G Brooks; Philip A Arlen; Lianying Gao; Christina M R Kitchen; Jerome A Zack
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

3.  Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection.

Authors:  Viktor Müller; Javier Flavio Vigueras-Gómez; Sebastian Bonhoeffer
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

Review 4.  Latency in human immunodeficiency virus type 1 infection: no easy answers.

Authors:  Deborah Persaud; Yan Zhou; Janet M Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

5.  Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments.

Authors:  David C Nickle; Mark A Jensen; Daniel Shriner; Scott J Brodie; Lisa M Frenkel; John E Mittler; James I Mullins
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

6.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

7.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.

Authors:  Tae-Wook Chun; David C Nickle; J Shawn Justement; Danielle Large; Alice Semerjian; Marcel E Curlin; M Angeline O'Shea; Claire W Hallahan; Marybeth Daucher; Douglas J Ward; Susan Moir; James I Mullins; Colin Kovacs; Anthony S Fauci
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

8.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Endothelial cells promote human immunodeficiency virus replication in nondividing memory T cells via Nef-, Vpr-, and T-cell receptor-dependent activation of NFAT.

Authors:  Jaehyuk Choi; Jason Walker; Kristina Talbert-Slagle; Paulette Wright; Jordan S Pober; Louis Alexander
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Primary cell model for activation-inducible human immunodeficiency virus.

Authors:  Bryan Burke; Helen J Brown; Matthew D Marsden; Gregory Bristol; Dimitrios N Vatakis; Jerome A Zack
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.